Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
=== Consumer healthcare === GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh, Macleans and Sensodyne toothpastes. GSK also previously owned the Lucozade and Ribena brands of soft drinks, but they were sold in 2013, to Suntory for £1.35bn. Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements. In March 2014, it recalled Alli, an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints. On 18 July 2022, GSK formally spun off its consumer healthcare business as a separate entity, Haleon.
=== Mechanism of action === Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. At the GLP-1 receptor, though, tirzepatide shows bias toward cAMP (a messenger associated with regulation of glycogen, sugar, and lipid metabolism) generation rather than β-arrestin recruitment. This combination of preference toward GIP receptor and distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion. Tirzepatide has been reported to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage.
== Future of Bradford Protein Assay == New modifications for an improved Bradford Protein Assay have been underway that specifically focuses on enhancing detection accuracy for collagen proteins. One notable modification involves incorporating small amounts, approximately .0035%, of sodium dodecyl sulfate (SDS). This inclusion of SDS has been shown to result in a fourfold increase in color response for three key collagen proteins—Collagen types I, III, and IV—while simultaneously decreasing the absorbance of non-collagen proteins, to bring the response curve closer between non-collagen protein and collagen protein. This simple modification in the preparation of the reagent resulted in Bradford Assays to produce similar response curves for both collagen and non-collagen proteins, expanding the use of Bradford Assays in samples containing high collagen proteins.
The nephrotic syndrome is characterised by the finding of edema in a person with increased protein in the urine and decreased protein in the blood, with increased fat in the blood. Inflammation that affects the cells surrounding the glomerulus, podocytes, increases the permeability to proteins, resulting in an increase in excreted proteins. When the amount of proteins excreted in the urine exceeds the liver's ability to compensate, fewer proteins are detected in the blood – in particular albumin, which makes up the majority of circulating proteins. With decreased proteins in the blood, there is a decrease in the oncotic pressure of the blood. This results in edema, as the oncotic pressure in tissue remains the same. Although decreased intravascular oncotic (i.e. osmotic) pressure partially explains the patient's edema, more recent studies have shown that extensive sodium retention in the distal nephron (collecting duct) is the predominant cause of water retention and edema in the nephrotic syndrome. This is worsened by the secretion of the hormone aldosterone by the adrenal gland, which is secreted in response to the decrease in circulating blood and causes sodium and water retention. Hyperlipidemia is thought to be a result of the increased activity of the liver.
Sources: en.wikipedia.org
Implementing feed-stocks of high specific activity 99Mo solutions thus allowed for higher quality production and better separations of 99mTc from 99Mo on small alumina column using chromatography. Employing low-specific activity 99Mo under similar conditions is particularly problematic in that either higher Mo loading capacities or larger columns are required for accommodating equivalent amounts of 99Mo. Chemically speaking, this phenomenon occurs due to other Mo isotopes present aside from 99Mo that compete for surface site interactions on the column substrate. In turn, low-specific activity 99Mo usually requires much larger column sizes and longer separation times, and usually yields 99mTc accompanied by unsatisfactory amounts of the parent radioisotope when using γ-alumina as the column substrate. Ultimately, the inferior end-product 99mTc generated under these conditions makes it essentially incompatible with the current supply chain. In the last decade, cooperative agreements between the US government and private capital entities have resurrected neutron capture production for commercially distributed 99Mo/99mTc in the United States of America. The return to neutron-capture-based 99Mo has also been accompanied by the implementation of novel separation methods that allow for low-specific activity 99Mo to be utilized.
=== European Union === In the European Union, a biological medicinal product is one of the active substance(s) produced from or extracted from a biological (living) system, and requires, in addition to physicochemical testing, biological testing for full characterisation. The characterisation of a biological medicinal product is a combination of testing the active substance and the final medicinal product together with the production process and its control. For example:
Greenland is an autonomous territory of the Kingdom of Denmark, and has been associated with the Scandinavian kingdoms of Denmark and Norway for more than a millennium, beginning in 986 AD when Norse settlers from what is now Norway and Iceland settled Greenland. The 13th century saw the arrival of the Inuit, the ancestors of today's majority population. After around 400 years, the Norse settlement in Greenland is believed to have died out in the late 15th century, but the legends of it persisted in Scandinavia. This prompted King Christian IV to send an expedition to Greenland in 1605 to locate the lost Eastern Norse Settlement and reassert sovereignty over Greenland. Norwegian priest Hans Egede reestablished a permanent Dano-Norwegian presence in 1721, founding the town of Godthaab (now Nuuk). Today's population is mainly Inuit, with a smaller Danish population, and many people are of mixed Inuit and Danish origin. Greenlanders often have close family, personal, and cultural ties to Denmark, with thousands living there. Greenland formally became part of the Kingdom of Norway in 1261, when the Norse inhabitants submitted to the King of Norway. Norway then entered a union with Denmark in 1380. Under the 1814 Treaty of Kiel, Greenland remained with the Danish Crown as part of the settlement with Sweden following the Napoleonic Wars. Denmark declared full sovereignty over all of Greenland, including the uninhabited parts, in 1921, in the aftermath of the Treaty of Versailles.
== Available forms == AzM is often used as active ingredient in organophosphate pesticides like Guthion, Gusathion (GUS), Gusathion-M, Crysthyron, Cotnion, Cotnion-methyl, Metriltrizotion, Carfene, Bay 9027, Bay 17147, and R-1852. This is why Guthion is often used as a nickname for AzM. Studies have shown that pure AzM is less toxic than GUS. This increased toxicity can be explained by the interactions between the different compounds in the mixture.
Following the 2010 general election, negotiations led to David Cameron becoming prime minister as the head of a coalition government with the Liberal Democrats – the youngest holder of the office since the 1810s and the first coalition government in the country's history since World War II. His premiership was marked by the effects of the Great Recession; these involved a large deficit in government finances that his government sought to reduce through austerity measures. His administration passed the Health and Social Care Act and the Welfare Reform Act, which introduced large-scale changes to healthcare and welfare. He also enforced stricter immigration policies, introduced reforms to education and oversaw the 2012 London Olympics. The government privatised the Royal Mail and some other state assets, and legalised same-sex marriage in England and Wales. The Scottish National Party (SNP) became dominant in Scotland over the decade, with a referendum on Scottish independence held in 2014, returning a negative result. When the Conservatives secured an unexpected majority in the 2015 general election, Cameron remained as prime minister, this time leading a Conservative-only government. Meanwhile, the Conservative's coalition partner, the Liberal Democrats, saw their worst result in the party's modern history. Also in 2015, the Labour Party elected Jeremy Corbyn as its leader, who was considered the most left-wing leader of the party since Michael Foot (1980–83). Cameron's second ministry was dominated by the 2016 referendum on the UK's continuing membership of the EU.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.